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Abstract Breast cancer is the leading cause of cancer deaths
among non-smoking women worldwide. At the moment the
treatment regime is such that patients receive different
chemotherapeutic and/or hormonal treatments dependent on
the hormone receptor status, the menopausal status and age.
However, in vitro sensitivity testing of tumor biopsies could
rationalize and improve the choice of chemo- and hormone
therapy. Lab-on-a-Chip devices, using microfluidic techni-
ques, make detailed cellular analysis possible using fewer
cells, enabling working with a patients’ own cells and
performing chemo- and hormone sensitivity testing in an ex
vivo setting. This article describes the development of two
microfluidic devices made in poly(dimethylsiloxane)
(PDMS) to validate the cell culture properties and analyze
the chemosensitivity of MCF-7 cells (estrogen receptor
positive human breast cancer cells) in response to the drug
staurosporine (SSP). In both cases, cell viability was
assessed using the life-stain Calcein-AM (CAAM) and the
death dye propidium iodide (PI). MCF-7 cells could be
statically cultured for up to 7 days in the microfluidic chip. A
30 min flow with SSP and a subsequent 24 h static
incubation in the incubator induced apoptosis in MCF-7
cells, as shown by a disappearance of the aggregate-like
morphology, a decrease in CAAM staining and an increase
in PI staining. This work provides valuable leads to develop
a microfluidic chip to test the chemosensitivity of tumor cells
in response to therapeutics and in this way improve cancer
treatment towards personalized medicine.
Keywords Breastcancer.Apoptosis.Viability.
Cytostaticdrugs.Lab-on-a-Chip
1 Introduction
Breast cancer is the leading cause of cancer among non-
smoking women in the world, although variation in
incidence, prevalence and mortality exists between countries
(Bray et al. 2004).
Treatment modalities used in breast cancer include
surgical removal of the tumor, followed by radiotherapy,
chemotherapy and/or hormone therapy. The various proto-
cols that exist for chemotherapy and hormone therapy have
different and limited rates of success (EBCTG 2005).
Currently, selection of chemotherapy and/or hormone
therapy is based on a broad scale of factors, including a
patients’ age and tumor characteristics, such as nodal status,
the presence of estrogen receptors and the Her-2/neu status
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Enschede, The Netherlands(Carney et al. 2007). One potential approach to improve the
therapeutic efficacy is to use ex vivo approaches to evaluate
the sensitivity to specific hormone therapies and chemo-
therapeutic agents using patients’ tumor cells. This requires
the harvesting of tumor cells via biopsy, conducting chemo-
and hormone sensitivity tests and extrapolating the results
to the clinical setting.
Microfluidic devices are very helpful inthe designof such
chemo- and hormone sensitivity tests for multiple reasons.
Microfluidic devices offer the possibility of using lower
quantities of cells, parallel processing (high-throughput
analysis) and detailed cellular analysis (Andersson and van
den Berg 2003, 2004). Because of the lower quantities of
cells (typically <100), cells can even be obtained via fine-
needle aspiration. Furthermore, the obtained cells can be
subdivided into numerous samples to test various concen-
trations and combinations of different chemotherapeutics
and hormones (high-throughput drug screening). Further-
more, individually tested samples in parallel promotes
statistical analysis.
The balance between programmed cell death (apoptosis)
and cell proliferation determines the tumor growth rate, and
any alteration between these two factors may be the key
element for the uncontrolled expansion of malignant
tumors. Chemotherapeutics and/or hormones are prescribed
to tackle this homeostatic imbalance. Conventional apopto-
sis and proliferation assays were performed to evaluate the
hormone sensitivity of different breast cancer cell lines in
vitro (Franke and Vermes 2002, 2003; Franke et al. 2003;
Werner et al. 2005). Attempts of testing chemosensitivity of
tumor cells ex vivo were already made in the eighties, but
have not developed into a standard chemosensitivity test so
far (Selby and Raghaven 1981). Recently, research groups
have established a link between clinical responses to
chemotherapeutics and ex vivo chemosensitivity analysis
(Nakada et al. 2005; Yamashita et al. 2005; Trojan et al.
2005). Moreover DNA microarrays (Gianni et al. 2005) and
multiparametric microsensor chips (Otto et al. 2003) have
been developed for chemosensitivity testing. The assays
described above provide valuable leads for novel therapeu-
tic modalities and improve cancer treatment, however there
are limitations. For example, the in vitro hormone sensitiv-
ity assays need cell culture to obtain millions of cells for
analysis and the techniques are very time-consuming and
extremely laborious. Cell handling is easier with DNA
microarrays, however, the link between genetics and the
ultimate goal, cell death in response to chemotherapeutics,
yields uncertainty and adds to statistical difficulties.
The focus of this article is to develop a microfluidic chip
which enables the analysis of the chemosensitivity of first
breast cancer cell lines, and in a later stage a patients’ own
breast cancer cells in the presence of various chemo-
therapeutics. As the goal of chemotherapy is to induce cell
death, the degree of apoptosis was assessed using fluores-
cent dyes. It is not until recently that research groups have
become interested in developing chips convenient for
detecting apoptosis (Wolbers et al. 2004a, b; Qin et al.
2005). So far, microfluidic chips have been developed to
characterize the various hallmarks in the apoptotic cascade
in real-time at a single-cell level using fluorescent dyes
(Valero et al. 2005; Munoz-Pinedo et al. 2005; Chan et al.
2003), measuring the release of biological substances
(Tamaki et al. 2002; Kurita et al. 2003), and the fragmen-
tation of the DNA (Kleparnik and Horky 2003). Apoptosis
assays place greater demands on cell handling, especially
when cell culture of adherent cells is required. Therefore it
has to be ensured that the microfluidic device and
experimental set-up do not negatively influence the cellular
behavior prior to adding chemotherapeutics (Wolbers et al.
2006). Besides the fact that the microfluidic device and
experimental set-up must be compatible with cell survival,
a flow system is needed to deliver medium and chemo-
therapeutics. The applied flow rate and the accompanied
shear stress have to ensure cell survival. For the chip
material, the silicone elastomer poly(dimethylsiloxane)
(PDMS) together with glass, for sealing, is chosen. PDMS
is biocompatible, gas permeable, and a cheap material in
which structures on a micrometer scale can be easily made
(McDonald et al. 2000; Sia and Whitesides 2003), and
Pyrex glass is a good supporting material for cell adhesion
and promotes optical analysis. Overall, the microfluidic
device and flow system consist of disposables, which is a
great advantage when performing biological experiments.
This paper describes the cellular studies performed on the
estrogen receptor positive human invasive lobular carcino-
ma cell line MCF-7 in two different microfluidic PDMS
chips. Firstly, a low volume microfluidic device with cell
trap was used to evaluate cell culture. Secondly, a chip with
a higher volume without cell trap was used to apply a
controlled flow of medium and a chemotherapeutic to study
the effect of this drug on the apoptotic pathway. In the
experiments presented here, apoptosis is induced by the
protein kinase C (PKC) inhibitor staurosporine (SSP;
Koivunen et al. 2006) to optimize the microfluidic device
towards a potential clinically relevant apoptosis assay.
Staurosporine is a frequently used agent for the induction
of apoptosis, and known to induce apoptosis in MCF-7 cells
(Mooney et al. 2002; Xue et al. 2003; Sayeed et al. 2007).
In a later stage, specific chemotherapeutic agents for breast
cancer, such as cyclophosphamide or doxorubicin (anthra-
cyclin) will be used. Cell viability was assessed using two
fluorescent dyes, i.e., the life-stain Calcein-AM (CAAM;
Bratosin et al. 2005) and the death dye propidium iodide
(PI; Zamai et al. 2001). This work provides us with valuable
leads to develop a microfluidic chip to test the chemo-
sensitivity of tumor cells and improve cancer treatment.
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2.1 Chip design and fabrication
2.1.1 Chip 1
Chip 1 consists of a single channel with a length of 1 cm, a
width of 200 μm and a depth of 50 μm. The round inlet and
outlet have a diameter of 1.5 mm. The total channel volume
is ~0.1 μl. The middle of the channel consists of vertical
columns (17 μm wide, 10 μm length, 40 μm depth)
separated by 5 μm spaces, acting as a trapping structure
(Fig. 1). The structures were made in PDMS (Sylgard 184,
Dow Corning). Curing and base agent were mixed at a ratio
of 1:10 for 15 min and degassed. PDMS was poured on the
FDTS-coated patterned silicon wafer, degassed, and cured
at 60° for 24 h.
After curing, holes were punctured in the PDMS, creating
an in- and outlet. The PDMS chip was sealed onto a slide of
Pyrex glass (1×2 cm) using oxygen plasma. Therefore, the
PDMS and Pyrex glass were cleaned with acetone and
ethanol. The surfaces were placed in the plasma oxygenator
(Harrick PDC001) for 4 min at an RF of 29.6 W and a
pressureof400 mTorr(high).After sealing,phosphatebuffer
saline (PBS) was introduced into the chip to preserve the
hydrophilicity of the PDMS and facilitate cell loading.
2.1.2 Chip 2
Chip 2 consists of a main channel, which broadens into a
chamber for cell culture. The inlet and outlet channel have a
width of 1.5 mm and a depth of 44 μm. The cell culture
chamber has a length of 10 mm, a width of 5 mm and a
depth of 44 μm. The cell culture chamber includes an array
of pillars to increase the stability of the chamber.
Furthermore, chip 2 consists of two secondary inlets for,
for example, the optional addition of versene or fluorescent
dyes. The total volume is 4.4 μl (Fig. 2(a)). The structures
were made in PDMS and sealed onto a microscope slide as
described above (Fig. 2(b)). After sealing, phosphate buffer
saline (PBS) was introduced into the chip to preserve the
hydrophilicity of the PDMS and facilitate cell loading.
2.2 Cell culture
The estrogen receptor positive human invasive lobular
carcinoma cell line MCF-7 was purchased from DSMZ
(Braunschweig, Germany). Cells weregrown inRoswell Park
MemorialInstitute (RPMI)-1640medium, supplementedwith
10% (v/v) fetal bovine serum (FBS), 100 IU/ml penicillin,
100 μg/ml streptomycin, 2 mM L-glutamine and 0.4 μg/ml
fungizone (RPMI
+ medium). Media and supplements were
all obtained from Invitrogen (Grand Island, NY, USA). Cell
cultures were sustained in a 5% CO2 humidified atmosphere
at 37°C. The medium was refreshed every 3–4 days and
cultures were split weekly at a ratio of 1:3–1:6 after
treatment with versene in distilled water. Versene consists
of distilled water with 137 mM NaCl, 1.47 mM KH2PO4,
2.68 mM KCl, 7.37 mM Na2HPO4·2H2O and 0.54 mM
NA2EDTA dissolved. In experiments, MCF-7 cells which
had satiated the conventional culture flasks (>80% conflu-
ence) were used for cell loading.
2.3 Experimental set-up
2.3.1 Chip 1
Cell loading was accomplished by pipetting cells in the
inlet. Hydrostatic forces moved the cells into the channels
and cells were trapped at the trapping site. The chip was put
in a Petri dish and covered with RPMI
+ medium to prevent
further flow. The chip was placed back in the incubator to
analyze long-term cell culture. For this, cells were cultured
for 1, 2, 3, 5 and 7 days, without changing the medium. For
every time point a separate chip was used. Viability was
assessed by staining the cells in the chip with 2 μg/ml
Fig. 1 Schematic drawing of
PDMS chip 1
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10 μg/ml Propidium Iodide (PI; Sigma, St. Louis, MO,
USA). Cell viability was obtained optically, checking cell
morphology with light microscopy and fluorescence with a
mercury lamp.
2.3.2 Chip 2
Cells were introduced by pipetting 20 μlo f4 × 1 0
6 cells/ml
in the inlet. Cells dispersed evenly throughout the chip by
hydrostatic forces. The chip was put in a Petri dish, covered
with RPMI
+ medium and placed in the incubator for 2 days.
The medium in the chip and in the Petri dish were refreshed
after 1 day. After 2 days, flow was applied. In the main
inlet, a pipette tip (Finntip 200Ext 5–200 μl; Thermo
Electron Corporation, Vantaa, Finland) was punctured, in
which a PA-6 (inner Ø 0.25 mm and outer Ø 0.75 mm;
Liquid scan) tube was put to connect it to a BD plastic
syringe (Becton Dickinson, Franklin Lanes, NJ, USA) via a
BD Microlance needle (30 G × 1/2 in.; 0.3×13 mm,
yellow). Flow was applied by a KdScientific 101 syringe
pump at a flow rate of 0.5 μl/min. The outlet and secondary
outlets were left open. Flow was applied for 30 min.
Apoptosis was induced by 50 μM staurosporine (SSP;
Sigma). RPMI
+ medium served as a control. After 30 min
of flow, the chip was disconnected from the flow system
and put in a Petri dish fully covered with RPMI+ medium
and placed in the incubator for 24 h.
After 24 h, the chip was connected to the flow system to
flow a solution of 2 μg/ml CAAM and 10 μg/ml PI through
the chip at a flow rate of 0.5 μl/min for 30 min. Cell viability
was obtained optically, checking cell morphology with light
microscopy and fluorescence with a mercury lamp.
2.4 Microscope system
The microfluidic chip was mounted on to an X–Y–Z
translation stage of an inverted wide fluorescence micro-
scope (Leica DM IRM, Leica Microsystems, Wetzlar,
GmbH, Germany). The microscope is equipped with a
mercury lamp as an excitation source for fluorescence
measurements, 5×, 10×, 20×, 50×, 63× objectives, and
different fluorescent cubes, of which the BGR filter cube
was used in these experiments (excitation BP 420/30
and emission BP 465/20 [blue]; excitation BP 495/15 and
emission BP 530/30 [green]; excitation BP 570/20 and
emission BP 640/40 [red]). In addition, a computer-
controlled CCD camera (Leica DFC300 FX) is mounted
on to the microscope for image recording, using the
accompanied Leica Application Suite Software (version
2.3.4 R2).
3 Results
3.1 Chip 1
For the culture of adherent cells in a microfluidic device,
cells must be able to adhere to the bottom of the chip. PDMS
is non-toxic and MCF-7 cells adhered optically. However
when the PDMS was rinsed the cells flushed away. Coating
with gelatin 1% or BSA 3% did not improve this. Possibly
other coating agents would improve adherence. Nonetheless
Pyrex glass was used for the cells to adhere (bottom of the
chip), since MCF-7 cells adhere to Pyrex glass without the
need of coating. Structures (upper part of the chip) were
made in PDMS because of its fabrication properties and
oxygen permeability.
Chip 1 consists of a cell trap, which promotes the
entrapment of MCF-7 cells in the middle of the channel
(Fig. 1). In this way, the amount of cells which could
adhere to the Pyrex glass, increased. Thus, the immediate
flow of cells from the inlet directly to the outlet was
prevented. By loading cells into the vertical inlet, it was
expected, due to the hydrophilicity of the chip, that medium
including cells would easily flow through the channel
because of hydrostatic forces. However, only part of the
loaded cells flew into the channel, others sank to the bottom
Fig. 2 Schematic drawing of PDMS chip 2 (a) and picture of the final chip design in PDMS sealed onto a microscope slide (b). Courtesy S. Le
Gac 2007
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size of the channel compared to the size of the inlet, the
used cell concentration or the stickiness of the cells. The
used cell concentration is convenient for the chip dimen-
sions of chip 1. MCF-7 cells are adherent epithelial-like
cells which grow in colonies, forming aggregates, as it is
the nature of these tumor cells. However, MCF-7 cells need
to be in suspension to transfer these cells into the chip. This
might account for the stickiness, and together with the
narrow channel, complicate the entrance into the channel.
In this way, a natural selection could occur due to
differences in stickiness. If stickiness is related to cell
viability, this could confound the viability analysis. In our
case, MCF-7 cells, cultured in a conventional culture flask,
were detached with versene, and immediately loaded in the
chip, to minimize the effect on the cell viability. Resus-
pending did not yield extra cells in the channel and possibly
damages the cells mechanically.
The MCF-7 cells (size≈10 μm) that entered the channel
were mechanically trapped (Fig. 3(a)). Although, the space
between the pillars is only 5 μm, cells were still able to pass
the cell trap. Moreover, the cells could flow underneath the
cell trap because the pillars have a height of 40 μm, in
comparison to the channel which has a depth of 50 μm.
Advantageously, the flow of medium was not obstructed by
the trapped MCF-7 cells, however, when the MCF-7 cells
formed a few rows in the cell trap the flow diminished. At
the cell trap, the round cells were compressed at a high
density, but during cell culture, the cells attached to the
Pyrex glass, retaining their epithelial-like morphology and
migrating away from the trap (Fig. 3(b) and (c)). Cell
culture was performed under static conditions on the
microscope stage at 37°C (thermoplate), using specific cell
culture medium, i.e., CO2 independent medium (Invitro-
gen), which is a non-HEPES proprietary medium suitable
for supporting cell growth under atmospheric conditions.
Furthermore, the viability of long-term cell culture of
MCF-7 cells was analyzed. In order to bring cells in their
exponentially growing phase (doubling time±50 h), cells
need to be cultured for 2–3 days before starting apoptosis
experiments. MCF-7 cells were trapped in chip 1 and
cultured in a conventional incubator. Cell viability was
checked after 1, 2, 3, 5 and 7 days using the life-stain
Calcein-AM (CAAM) and the death dye propidium iodide
(PI; Fig. 4). Viable cells stained green and dead cells red.
Medium in the channel was not changed, and for every time
point a separate chip was used, as fluorescent dyes are toxic
for cells. As demonstrated in Fig. 4, the majority of the
MCF-7 cells were viable, showing green CAAM staining
and negligible red PI fluorescence. It was observed that
MCF-7 cells migrated away from the trap in time, forming
aggregates in the channel, and because of this clustered cell
growth, quantifying the viability of the cells was difficult.
Nevertheless, plotting the course of the overall green
(CAAM), red (PI) and total fluorescent intensity in time
provides a good indication of the viability. The plot of
Fig. 4 shows an increase in the green fluorescence, defining
that the cell number has increased (proliferation). The red
fluorescence increases only slightly, indicating that some
cells have died, though the number is similar to what apply
for conventional cell culture. However, these viability results
maybe somewhat positively skewed because the introduc-
tion of the fluorescent dyes in the chip induced a flow,
resulting in lost of detached (including apoptotic bodies) or
loose cells that flew towards the outlet. Moreover, due to the
use of fluorescent dyes it was necessary to use a different
chip for every individual time point. Nevertheless, the same
pool and concentration of MCF-7 cells was used to perform
the 7-days viability experiments. Hence, it can be assumed
that cells survived and proliferated, since they were CAAM
positive (increase in fluorescent intensity in time) and
confluence increased, as shown in Fig. 4.
The viability experiments as described above were
performed without any medium change. For growth and
viability maintenance, MCF-7 cells were dependent on the
nutrients present in the medium in the channel and the
diffusion of nutrients through the inlet in the channel and
the diffusion of gases through the PDMS. The thickness of
Fig. 3 Static culture of MCF-7 cells in chip 1. Suspended MCF-7
cells were loaded in the chip and the cells which flew in the channel
were trapped at the cell trap (a). Cell culture was performed on the
microscope stage at 37°C (thermoplate) using specific cell culture
medium, i.e. CO2 independent medium. The round MCF-7 cells
attached to the Pyrex glass, retrieving their epithelial-like morphology
(b), and migrated away from the trap (b white arrows and c).
Magnification is ×10
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the inlet and outlet did not have any effect on cell viability
inside the channel. It could be observed that cell growth
was favored at spots where the cells were in direct contact
with the medium and had no PDMS on top (Fig. 5).
To conduct apoptosis experiments, a controlled flow was
required to (continuously) introduce the apoptotic inducer
in the microfluidic chip. Therefore, pipette tips were chosen
because of the simplicity and the disposability. Unfortu-
nately, it was not possible to use pipette tips to apply a
controlled flow in chip 1, because puncturing a pipette tip
in the inlet caused a sudden, strong flow (which detached
the cells) as a result of the large volume of the pipette tip in
comparison with the channel volume. To reduce this sudden
strong flow, a new chip was developed (chip 2), with
dimensions which enabled the connection to the flow
system with use of pipette tips.
3.2 Chip 2
As shown in Fig. 2, chip 2 consists of a larger surface area
to culture cells. Due to widening of the channel, cell
loading was improved. In this case, MCF-7 cells were
loaded at a higher concentration (20 μl4 × 1 0
6 cells/ml),
since the surface is larger and there is no cell trap. The cells
were introduced into the chip with a pipette tip and easily
dispersed over the surface. In this chip design, the rapid
deceleration and compression of cells, which did occur at
the cell trap in chip 1, was prevented. After 2 days in the
incubator for cell culture, chip 2 was connected to the flow
system. This also caused a displacement of liquid in the
chip, however, because of the larger dimensions, the MCF-
7 cells did not detach. A flow of 0.5 μl/min for 30 min was
applied, either containing RPMI
+ medium for the control
group, or 50 μM staurosporine (dissolved in RPMI
+
medium) for the apoptosis group. To prevent cellular
disfunction and preserve the viability of MCF-7 cells under
flow conditions, the duration of the flow was kept short and
the flow rate as low as possible to have a minimal effect of
the shear stress (<<0.5 dyn/cm
2), but ensure that all cells
have been in contact with the apoptotic inducer. Due to this
short period, the use of specific CO2 independent medium
was not necessary. After 24 h, the viability of the MCF-7
cells was checked with CAAM and PI. Figure 6 shows that
Fig. 4 Long-term static cell culture of MCF-7 cells in chip 1.
Viability was assessed using the life-stain Calcein-AM (CAAM;
green) and the death dye propidium iodide (PI; red). LM pictures with
underneath the corresponding fluorescent pictures are shown for the
different time periods. Magnification of the first four pictures (t=1 day
till t=5 days) is ×10 and for the last picture (t=7 days) is ×20. Plot
below the pictures shows the course of the overall green (CAAM), red
(PI) and total fluorescent intensity during the 7 days of culture. Note
that the picture of t=7 days is taken with a higher magnification than
the pictures of t=1 day till t=5 days. This also accounts for the
increase in the fluorescent intensity at t=7 days
732 Biomed Microdevices (2008) 10:727–737the majority of the MCF-7 cells in the control group
(Fig. 6(a)) maintained an aggregate-like cell pattern,
appearing in colonies. Most of the MCF-7 cells in the
control group were viable, as shown by the green CAAM
staining. However, some PI positive (red) cells could be
observed, present as small red dots surrounding the (green)
colony. In conventional cell culture, the amount of
apoptosis is normally between 5% and 10%, comparable
with the results shown in Fig. 6(a). When MCF-7 cells were
subjected to a flow with SSP, the aggregate-like phenotype
disappeared (the size of the colonies decreased), and cells
were predominantly present in small clusters. Incubation
with SSP demonstrated more PI positive cells (Fig. 6(b)) as
compared to the control group (Fig. 6(a)). Plotting the green
(CAAM) vs. the red (PI) fluorescent intensity (Fig. 7)
shows that the addition of SSP to MCF-7 cells decreased
this green:red ratio (control 0.74±0.19 vs. SSP 0.47±0.15),
which occurred due to a decrease in the fluorescence of the
life-stain and an increase in the fluorescence of the death
dye. Thus, SSP induced apoptosis in MCF-7 cells. Even
more, this effect is probably even larger, because due to the
applied flow to add the fluorescent dyes, part of the dead
cells washed away.
3.3 Discussion
3.4 Goals and obstacles
Matching cancer patients to the appropriate chemothera-
peutics would increase the effectiveness of these pharma-
ceuticals. Microfluidic devices have the potential to aid in
this process. For microfluidic devices to fulfill their
potential multiple obstacles must be taken. For example,
cells obtained via biopsy have to survive in the microfluidic
device and the obtained results have to be extrapolated to
the clinical situation. This paper described the first steps
towards a microfluidic device which enables chemosensi-
tivity testing of breast cancer cells to improve treatment.
The requirements for such assays were analyzed in two
different PDMS chips. The first design was used to explore
the cell culture properties of MCF-7 cells in the micro-
fluidic device and the second design to test the chemo-
sensitivity in response to the apoptotic agent staurosporine.
However, it should be stated that the microfluidic device
and experimental set-up as described in this paper is not
specific for breast cancer, but applicable for other (cancer)
cell lines and any other drug of interest to fine-tune multiple
therapies and the treatment of diseases, in which specifi-
cally the process of apoptosis is suppressed or enhanced.
3.5 Chip design and cell culture
In apoptosis assays it is essential that the chip design and
materials used create a microfluidic environment that meets
cellular needs and sustains cellular viability (Wolbers et al.
2006). MCF-7 cells have been cultured in microfluidic
devices, either in a 3D-cone structure (Torisawa et al. 2005)
or a channel device to which continuous flow was applied
(Neville et al. 2007). In our microfluidic PDMS-glass
device type 1, cell viability was maintained for up to 7 days
in a static cell culture fashion in the incubator. It is
described that the thickness of the PDMS has an influence
on the permeation of gasses such as O2 and CO2 (Leclerc
et al. 2003), however, in our experiments PDMS with a
thickness range in between 100 μm to several mm showed
to have no influence on the cell viability (data not shown).
Cell survival is also dependent on the quality of the
available medium. A higher concentration of cells will
exhaust the medium faster, however, cell–cell contacts are
necessary for survival (Yu et al. 2005). During long-term
cell culture no flow was applied in the microchannel. This
could have had an adverse effect on cell survival and
proliferation because of acidification of the medium and
depletion of nutrients (Zhu et al. 2004). However, Fig. 4
shows that cells managed to survive and proliferated in the
medium present in the chip for up to 7 days. Although
observed in a different cell line and in a microchannel with
dimensions in the mm range, the relationship between the
microchannel geometry and cell proliferation was explored
(Yu et al. 2005). It was described that cells cultured in
microchannels in the absence of flow proliferated signifi-
cantly more slowly than cells cultured in conventional
culture flasks, and entered a quiescent state. However, this
inhibited cell proliferation disappeared when cells returned
to a conventional culture flask. A possible explanation for
Fig. 5 LMpicture of the cell growth ofMCF-7 cells atthe inlet atday 5.
Cell growth was better at the medium side, forming confluent cell
cultures, whereas the cell growth under the PDMS was less pronounced.
Magnification is ×20. The dotted line shows the dividing line between
cell cultured under the PDMS or in direct contact with the medium
Biomed Microdevices (2008) 10:727–737 733the inhibited proliferation is that (cell-secreted) functional
molecules surround the cells, enclosing the cell in a special
microenvironment. Figure 5 of this paper also showed that
cells grew better under a ceiling of only medium (in the
punctured part) than under the ceiling of medium and
PDMS. This suggests that the culture conditions change
and even possibly deteriorate rapidly when under a PDMS
ceiling, because of the lack of diffusion, causing the cells
not to die, but entering a quiescent state.
Applying a continuous flow is a possible solution to
provide the cells with the appropriate amount of nutrients
and oxygen, and to remove waste products (Hung et al.
2005). However, the applied flow rate will expose the cells
to mechanical forces, such as the shear stress. The
maximum amount of shear stress that can be endured by
cells depends on the cell type, since certain cells (e.g.,
endothelial cells) require shear stress for their development,
whereas other cell types are negatively affected by shear
stress (such as chondrocytes; Li et al. 2005; Healy et al.
2005; Kim et al. 2007). The optimal flow rate is therefore
different for every cell type and chip design, depending on
the chip dimensions. MCF-7 cells are from an epithelial
origin, hence they do not require a (high) shear stress for
development. In this case, the optimal flow rate needs to
provide a good balance between on the one hand favorable
medium conditions and on the other hand a low as possible
shear stress. As stated in the results section, a flow of
0.5 μl/min was applied in chip 2, resulting in a shear stress
of 0.17 dyn/cm
2 in the inlet and outlet channel. The shear
stress in the cell culture chamber is even lower, due to
broadening of the channel and the presence of micropillars.
This flow rate did not affect the cellular viability, though it
could be observed that after 60 min of flow, the
characteristic colony-forming growth pattern diminished
and individual cells could be identified (data not shown).
Applying a continuous flow could introduce a confounding
Fig. 6 MCF-7 cells cultured in
chip 2. MCF-7 cells were incu-
bated with 50 μM staurosporine
(SSP) under a continuous flow
of 30 min (b). MCF-7 cells
flown with RPMI
+ medium
served as a control (a). There-
after, MCF-7 cells were put in a
Petri dish and placed in the
incubator for 24 h. After 24 h,
the chip was connected again to
the flow system to flow CAAM
(green) and PI (red), to check
the viability. This figure shows
the LM pictures after fluorescent
staining, with underneath the
corresponding fluorescent pic-
tures. White squares and circles
highlight the pillars in the chip.
Magnification is ×20
734 Biomed Microdevices (2008) 10:727–737variable in the apoptosis assays. To prevent this, the shear
stress needs to be reduced by further decreasing the flow
rate, changing the chip dimensions, or applying flow in
intervals. In our experiments flow was applied for only
30 min, which preserved the cellular viability (Fig. 6).
3.6 Apoptosis induction
To analyze the chemosensitivity of MCF-cells apoptosis
assays were performed. Staurosporine induced apoptosis in
MCF-7 cells, exhibiting a diminished aggregate-like pheno-
type and PI positivity (Fig. 6). Morphology and fluorescence
analysis are widely used in apoptosis assays. For an
apoptosis assay to be useful the assay has to be controllable
and apoptosis rates must be quantifiable and repeatable.
Quantification of apoptosis in adherent cells that grow in
colonies and maybe even in layers is only indicative when
solely relying on optical methods, and therefore it is better to
implement the measurement of electrophysiological param-
eters, such as pH, pO2 and impedance measurements (Otto et
al. 2003). Furthermore, this aggregate-like phenotype com-
plicates the interaction of the drug with all cells separately,
hence probably not every cell was exposed to the same drug
concentration during the 30 min of flow and the subsequent
24 h incubation. Moreover, the cells that in the final stage of
the apoptotic process have detached from the surface and
flow towards the outlet have to be counted in. In the
experiments presented here, these detached cells were not
included, so the amount of apoptosis observed might be an
underestimation, for not only the untreated cells, but
especially the SSP-treated cells. The chemosensitivity results
obtained in the microfluidic chip are difficult to compare
with standard conventional assays, such as flow cytometry,
due to differences in experimental settings. The chosen
staurosporine concentration used in our experiments was
substantial higher than described in literature, in order to
assure quick apoptotic effects in our caspase-3 negative
MCF-7 cells (Mooney et al. 2002; Xue et al. 2003; Sayeed et
al. 2007). The implementation of a dose-gradient generator
in future chip designs will enable dose–response analysis
(Thompson et al. 2004).
3.7 External validity and future plans
If eventually the chip as described here is optimized to
serve as a solid apoptosis assay to analyze drug responses,
it will still be doubtful if in vivo cancer sensitivity to a
certain chemotherapeutic agent can be predicted by in vitro
testing. It is impossible to copy in vivo circumstances to the
in vitro situation. However the quality of the model
depends on predicting chemosensitivity, not on the resem-
blance between the in vitro and the in vivo environment.
For testing chemosensitivity, apoptosis assays were chosen
since apoptosis is the objective and most downstream effect
of chemotherapy. DNA microarrays have less requirements
regarding cell handling, nevertheless are more upstream.
The uncertain link between genetics and apoptosis in
response to certain chemotherapeutics introduces more
variability. Breast tumors are heterogeneous and the cells
of a single tumor could be heterogeneous because of tissue
conditions (ischemia and necrosis) (Stingl and Caldas
2007). Therefore, it is essential to use a patients’ own (tumor)
cells obtained via biopsy and perform experiments in an ex
vivo setting. For high-throughput analysis, the obtained cells
can be subdivided into numerous samples to test various
concentrations (dose-gradient generator) and combinations of
different chemotherapeutics. The objective of such a high-
throughput analysis would be to rank different available
chemotherapeutics based on their effectiveness for the
specific tumor of a specific patient. In this way patient
Fig. 7 Plot of the overall green
(CAAM) vs. the red (PI) fluo-
rescence of the individual pic-
tures shown in Fig. 6: left,
middle and right (small
squares), respectively, for the
control (empty squares) and
staurosporine (SSP; filled
squares) treated MCF-7 cells.
Average (big square) defines the
mean of the measured green:red
fluorescent intensities of the
three individual pictures (small
squares), with the accompanied
SD
Biomed Microdevices (2008) 10:727–737 735survival can be increased and costs decreased. Specific for
breast cancer patients, such an assay could be used for
example to decide between a cyclophosphamide-methotrex-
ate-5-fluorouracil (CMF) treatment or an anthracyclin con-
taining agent. For this, a detailed validation of the chip in a
clinical setting is greatly required.
Our future plans are first focused on optimizing the
experimental set-up and be able to quantify apoptosis
percentages, which is possible in conventional flow
cytometry analyses (Wolbers et al. 2004a, b)a n di n
multiparametric tests on chip (Gouaze et al. 2002; Mooney
et al. 2002; Otto et al. 2003). Quantifying apoptosis makes
it easier to correlate the obtained values with results
published in literature, and undertake steps towards the
clinic. This will increase the chemotherapeutic effectiveness
and improve personal heath care. Although there is an
increasing knowledge about the different chemotherapeu-
tics and intracellular pathways, in our opinion one of the
reasons for lack of chemotherapeutic effectiveness arise
from the fact that there are hardly any predictive tests to
match patients to chemotherapeutics.
4 Conclusion
In this paper the development towards a microfluidic chip
which enables the cultivation of cells and the induction of
apoptosis using a flow system is described. We found that
MCF-7 cells could be cultivated statically for up to 7 days in
a microfluidic PDMS-Pyrex chip. Upon induction of
apoptosis with SSP, the characteristic aggregate-like pheno-
type disappeared, and MCF-7 cells were predominantly
present in small PI positive clusters. Compared to untreated
MCF-7 cells, SSP diminished the ratio of the fluorescence of
the life-stain CAAM vs. the fluorescence of the death dye PI
with almost a factor 2, indicating that apoptosis is induced.
Next steps are focused on validating this device using
clinically relevant hormone and chemotherapeutic agents in
combination with patients’ tumor cells, to prove the
importance of such a device for the clinic.
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